Ashaka Vansia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ashaka Vansia has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Pravin Dudhagara
Department of Biosciences, Veer Narmad South Gujarat University, India
3 shared publications - Rajesh Patel
Department of Biosciences, Veer Narmad South Gujarat University, India
3 shared publications - Anjana Ghelani
Department of Microbiology, Shree Ramkrishna Institute of Computer Education and Applied Sciences, Surat 395001, India
2 shared publications - Douglas J. H. Shyu
Department of Biological Science and Technology, National Pingtung University of Science and Technology, Pingtung 912301, Taiwan
2 shared publications - Komal Antaliya
Department of Biosciences, Veer Narmad South Gujarat University, Surat, India
2 shared publications - Nilam Vaghamshi
Department of Biosciences, Veer Narmad South Gujarat University, Surat 395007, India
2 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
Environmental emergence and dissemination of clinically relevant multidrug-resistant bacteria and resistance genes in sewage and aquatic ecosystems
Osong Public Health and Research Perspectives
- 23 July 2026
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
Open AccessEnvironmental emergence and dissemination of clinically relevant multidrug-resistant bacteria and resistance genes in sewage and aquatic ecosystems
Osong Public Health and Research Perspectives
- Open Access
- 18 January 2026
- Published by MDPI AG in Microbiology Research
- Vol. 17 (1) , 25
Preliminary Assessment of Cow-Derived Fermented Product (CDFP) Effects on the Human Gut Microbiome: A Single-Subject Case Study
Cow’s milk, urine, dung, ghee, and curd possess significant medicinal value in Ayurveda and have been integral to traditional Indian clinical practices for centuries. The cow-derived fermented product (CDFP), a formulation rooted in Ayurvedic tradition, combines these five components as a panchgavya and is believed to offer multifaceted health benefits. In this preliminary single-subject case study, we evaluated the microbial composition of CDFP itself and assessed its effects on the human gut microbiome before and after 7 and 15 days of administration. A single healthy male subject consumed CDFP daily for seven consecutive days. Using 16S rRNA metagenomic sequencing, we observed a prominent increase in gut microbial diversity and a rise in beneficial bacterial genera such as Bifidobacterium, Faecalibacterium, and Akkermansia during and after treatment. Functional profiling revealed significant enhancements in pathways associated with amino acid metabolism, vitamin biosynthesis (e.g., folate, riboflavin), and energy metabolism, along with transient boosts in secondary metabolite synthesis. Metabolomic analysis identified 171 bioactive compounds within CDFP, with 33 exhibiting interactions with human proteins involved in immune modulation, oxidative stress response, and gut barrier integrity. Although conducted on a single participant, this study is the first to elucidate the distinct changes observed in gut microbial composition and function following the seven-day CDFP regimen and provides initial insights that warrant further investigation in larger, controlled studies. These findings highlight the potential of CDFP as a microbiota-targeted intervention with health-supportive properties.
- 18 January 2026
- Published by MDPI AG in Microbiology Research
- Vol. 17 (1) , 25
Open AccessPreliminary Assessment of Cow-Derived Fermented Product (CDFP) Effects on the Human Gut Microbiome: A Single-Subject Case Study
Cow’s milk, urine, dung, ghee, and curd possess significant medicinal value in Ayurveda and have been integral to traditional Indian clinical practices for centuries. The cow-derived fermented product (CDFP), a formulation rooted in Ayurvedic tradition, combines these five components as a panchgavya and is believed to offer multifaceted health benefits. In this preliminary single-subject case study, we evaluated the microbial composition of CDFP itself and assessed its effects on the human gut microbiome before and after 7 and 15 days of administration. A single healthy male subject consumed CDFP daily for seven consecutive days. Using 16S rRNA metagenomic sequencing, we observed a prominent increase in gut microbial diversity and a rise in beneficial bacterial genera such as Bifidobacterium, Faecalibacterium, and Akkermansia during and after treatment. Functional profiling revealed significant enhancements in pathways associated with amino acid metabolism, vitamin biosynthesis (e.g., folate, riboflavin), and energy metabolism, along with transient boosts in secondary metabolite synthesis. Metabolomic analysis identified 171 bioactive compounds within CDFP, with 33 exhibiting interactions with human proteins involved in immune modulation, oxidative stress response, and gut barrier integrity. Although conducted on a single participant, this study is the first to elucidate the distinct changes observed in gut microbial composition and function following the seven-day CDFP regimen and provides initial insights that warrant further investigation in larger, controlled studies. These findings highlight the potential of CDFP as a microbiota-targeted intervention with health-supportive properties.
- Open Access
Biogenic Synthesis of Antibacterial, Hemocompatible, and Antiplatelets Lysozyme Functionalized Silver Nanoparticles through the One-Step Process for Therapeutic Applications
To evaluate silver nanoparticles’ (AgNPs) therapeutic and clinical potentials, antibacterial action, blood compatibility, and antiplatelet activities are the main concerns for toxicity profiling. Heat-denatured lysozyme-mediated formulation stabilized the AgNPs, thereby providing more bactericidal activity and blood compatibility. The study of the synthesis of AgNPs suggests the rapid and cost-effective formulation of AgNPs by one-step reaction using a 10:1 ratio of silver nitrate and lysozyme by incubating at 60 °C for two hours. Characterization of AgNPs was analyzed by UV–Visible spectroscopy, DLS, TEM, EDX, XRD, AFM, and FTIR, followed by antibacterial, hemocompatibility, and platelet aggregation testing. The average size of synthesized AgNPs was found to be 94.10 nm with 0.45 mV zeta potential and 0.293 polydispersity index by DLS. The TEM and EXD results indicated homogeneously 28.08 nm spherical-shaped pure formations of AgNPs. The XRD peaks showed the synthesis of small AgNPs with a crystallite size of 22.88 nm, while the AFM confirmed the homogeneity and smoothness of the monodispersed AgNPs. The FTIR spectra specified the coating of the lysozyme-derived amide group on the AgNPs surface, which provides stability and functionality of nanoparticles. The antibacterial activity of AgNPs was remarkable against six pathogenic bacteria and three multidrug resistance (MDR) strains (i.e., Escherichia coli, Klebsiella aerogenes, and Pseudomonas aeruginosa), which exhibited inhibition zones with diameters ranging between 13.5 ± 0.2 mm to 19.0 ± 0.3 mm. The non-hemolytic nature of the AgNPs was calculated by percentage hemolysis with four concentrations. The negative result of platelet aggregation using platelet-rich plasma suggests the antiplatelet effect of AgNPs. Only minor hemolysis of 6.17% in human erythrocytes and mild platelet aggregation of 1.98% were induced, respectively, by the use of 1000 µL of 1 mM AgNPs, which contains approximately 107.8 μg silver. The results indicated that the antiplatelet potency and non-hemolytic nature with the antibacterial action of the lysozyme functionalized AgNPs have a good chance to be used to solve in-stent restenosis and thrombosis issues of the coronary stent and may also have a possibility to use in vaccination to resolve the blood clotting problem. So, the optimized biogenic formulation of AgNPs offers promising opportunities to be used as a therapeutic agent.
Open AccessBiogenic Synthesis of Antibacterial, Hemocompatible, and Antiplatelets Lysozyme Functionalized Silver Nanoparticles through the One-Step Process for Therapeutic Applications
To evaluate silver nanoparticles’ (AgNPs) therapeutic and clinical potentials, antibacterial action, blood compatibility, and antiplatelet activities are the main concerns for toxicity profiling. Heat-denatured lysozyme-mediated formulation stabilized the AgNPs, thereby providing more bactericidal activity and blood compatibility. The study of the synthesis of AgNPs suggests the rapid and cost-effective formulation of AgNPs by one-step reaction using a 10:1 ratio of silver nitrate and lysozyme by incubating at 60 °C for two hours. Characterization of AgNPs was analyzed by UV–Visible spectroscopy, DLS, TEM, EDX, XRD, AFM, and FTIR, followed by antibacterial, hemocompatibility, and platelet aggregation testing. The average size of synthesized AgNPs was found to be 94.10 nm with 0.45 mV zeta potential and 0.293 polydispersity index by DLS. The TEM and EXD results indicated homogeneously 28.08 nm spherical-shaped pure formations of AgNPs. The XRD peaks showed the synthesis of small AgNPs with a crystallite size of 22.88 nm, while the AFM confirmed the homogeneity and smoothness of the monodispersed AgNPs. The FTIR spectra specified the coating of the lysozyme-derived amide group on the AgNPs surface, which provides stability and functionality of nanoparticles. The antibacterial activity of AgNPs was remarkable against six pathogenic bacteria and three multidrug resistance (MDR) strains (i.e., Escherichia coli, Klebsiella aerogenes, and Pseudomonas aeruginosa), which exhibited inhibition zones with diameters ranging between 13.5 ± 0.2 mm to 19.0 ± 0.3 mm. The non-hemolytic nature of the AgNPs was calculated by percentage hemolysis with four concentrations. The negative result of platelet aggregation using platelet-rich plasma suggests the antiplatelet effect of AgNPs. Only minor hemolysis of 6.17% in human erythrocytes and mild platelet aggregation of 1.98% were induced, respectively, by the use of 1000 µL of 1 mM AgNPs, which contains approximately 107.8 μg silver. The results indicated that the antiplatelet potency and non-hemolytic nature with the antibacterial action of the lysozyme functionalized AgNPs have a good chance to be used to solve in-stent restenosis and thrombosis issues of the coronary stent and may also have a possibility to use in vaccination to resolve the blood clotting problem. So, the optimized biogenic formulation of AgNPs offers promising opportunities to be used as a therapeutic agent.